A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction

• Published in: Asian journal of andrology Vol. 19; no. 4; pp. 500 - 504
• Main Authors: Bai, Wen-Jun, Li, Hong-Jun, Jin, Jian-Jun, Xu, Wen-Ping, Sebastian, Sorsaburu, Wang, Xiao-Feng
• Format: Journal Article
• Language: English
• Published: China Medknow Publications and Media Pvt. Ltd 01.07.2017; Medknow Publications & Media Pvt. Ltd; Medknow Publications & Media Pvt Ltd
• Subjects: Adult; Androgens; Angina pectoris; Asian Continental Ancestry Group; Clinical trials; Cross-Over Studies; Dosage and administration; Drug dosages; Drug therapy; Erectile dysfunction; Erectile Dysfunction - drug therapy; Erectile Dysfunction - psychology; Humans; Impotence; Interpersonal Relations; Male; Middle Aged; Original; Patient outcomes; Patient Preference; Patient Satisfaction; Patients; Personal relationships; Phosphodiesterase 5 Inhibitors - adverse effects; Phosphodiesterase 5 Inhibitors - therapeutic use; Quality; Quality of Life; Questionnaires; Sildenafil; Sildenafil Citrate - adverse effects; Sildenafil Citrate - therapeutic use; Socioeconomic Factors; Studies; Tadalafil; Tadalafil - adverse effects; Tadalafil - therapeutic use; Traditional Chinese medicine; Treatment Outcome; Young Adult; 临床试验; 勃起功能障碍; 枸橼酸西地那非; 治疗; 男性; 磷酸二酯酶抑制剂; 社会心理; 随机; China
• DOI: 10.4103/1008-682X.175782
• ISSN: 1008-682X

Sildenafil and tadalafil are efficacious and well tolerated in Chinese men with erectile dysfunction （ED）. Recent study results indicate that men with ED in China who were naive to phosphodiesterase inhibitor type 5 （PDE5） therapy prefer tadalafil 20-mg （on-demand） versus sildenafil 100-mg （on-demand）. Differences in psychosocial outcomes may help to explain treatment preference in favor of tadalafih This open-label, randomized, crossover study compared psychosocial outcomes and drug attribute choices between tadalafil and sildenafil in Chinese men with ED na＇（ve to PDE5 inhibitor therapy. Eligible patients were randomized to sequential 20-mg tadalafU/lOO-mg sildenafil （n = 190） or 100-mg sildenafil/20-mg tadalafil （n = 193） for 8 weeks each and were asked which treatment they preferred to take for the 8-week extension phase. Psychosocial outcomes were assessed using the Psychological and Interpersonal Relationship Scale （PAIRS）, Drug Attributes Questionnaire （DRAQ）, and Sexual Life Quality Questionnaire （SLQQ）. When taking tadalafil versus sildenafil, men had a higher mean endpoint score on the PAIRS Spontaneity Domain （tadalafil = 2.86 vs sildenafil = 2.72; P 〈 0.001）, and a lower mean endpoint score on the Time Concerns Domain （tadalafil = 2.41 vs sildenafil = 2.55; P 〈 0.001）. A numerical increase in the Sexual Self-Confidence Domain was observed when taking tadalafil versus sildenafil （tadalafil -- 2.76 vs sildenafil = 2.72; P= 0.102）. The most frequently chosen drug attributes explaining treatment preference were able to get an erection long after having drug, and ability to get an erection every time. SLQQ results were comparable between treatment groups. These psychosocial outcomes may explain why more Chinese men preferred tadalafil versus sildenafil for the treatment of ED in this clinical trial.